Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: TAVR

medical device deployed in the human heart

Assessing Efficacy of Cerebral Embolic Protection in TAVR by Geography

Post hoc analysis of PROTECTED TAVR finds reduced stroke risk in the U.S. but not beyond

20-HVI-2018223_aortic-valve-anatomy_650x450

Aortic Valve Replacement in Young and Middle-Aged Adults: New Data to Guide Decision-Making

Database analysis sets stage for a multicenter trial assessing TAVR’s potential role

20-HVI-1998311_TAVR valve_650x450

Valve Durability at 5 Years in PARTNER 2: SAPIEN 3 TAVR Matches SAVR, SAPIEN XT Doesn’t

Analysis used echocardiographic data to assess structural valve deterioration

19-HRT-5506-anticoagulation-650×450

Toward an Evidence-Based Approach to Anticoagulation After Bioprosthetic AVR

PARTNER 2 analysis finds few significant effects

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

18-HRT-5651-prosthetic-valve-endocarditis-650×450

Prosthetic Valve Endocarditis: No Difference with TAVR Vs. SAVR, Analysis Shows

Pooling of PARTNER data finds low rates regardless of approach

SapienXT-690×380

TAVR’s Reach Expands with Approval of New Indications and Next-Generation Valves

FDA approvals for valve-in-valve TAVR follow clearance of 3rd-generation valve

ACC-690×380

5-Year PARTNER 1B Results: TAVR Remains Superior to Standard Therapy for Inoperable Aortic Stenosis

Final outcomes report changes treatment paradigm

BackPage 1 of 1Next

Advertisement

Ad